MiNK Therapeutics (INKT) Stock Price, News & Analysis

Company Overview

MiNK Therapeutics, Inc. is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance. The company has established scalable, GMP‐compatible manufacturing processes to produce engineered exosomes at clinically relevant volumes. Research efforts focus on optimizing biodistribution, payload loading efficiency and safety profiles in animal models, with the goal of advancing IND‐enabling studies for first‐in‐human trials.

Headquartered in Cambridge, Massachusetts, MiNK collaborates with academic institutions and contract development organizations across North America and Europe to accelerate its research and development programs. The company’s integrated operations encompass discovery, preclinical testing and process development, supported by a team of experts in exosome biology, translational immunology and biomanufacturing. Through these partnerships and internal capabilities, MiNK aims to bring novel, precision immunotherapies to patients with high‐unmet‐need solid tumors.

Key Stats

• Today's Range: $13.85 to $14.85
• 50-Day Range: $12.06 to $17.50
• 52-Week Range: $4.56 to $76.00
• Volume: 37,220 shs
• Average Volume: 40,496 shs
• Market Capitalization: $63.28 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $37.50
• Consensus Rating: Hold

MiNK Therapeutics Stock Analysis - MarketRank™

MiNK Therapeutics scored higher than 57% of companies evaluated by MarketBeat, and ranked 449th out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Hold

Consensus Rating

MiNK Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, 1 hold rating, and 2 sell ratings.

Upside Potential

MiNK Therapeutics has a consensus price target of $37.50, representing about 167.9% upside from its current price of $14.00.

Amount of Analyst Coverage

MiNK Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for MiNK Therapeutics are expected to grow in the coming year, from ($2.75) to ($2.45) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of MiNK Therapeutics is -4.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of MiNK Therapeutics is -4.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.55% of the float of MiNK Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

MiNK Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in MiNK Therapeutics has recently increased by 1.03%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

MiNK Therapeutics does not currently pay a dividend.

Dividend Growth

MiNK Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.55% of the float of MiNK Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

MiNK Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in MiNK Therapeutics has recently increased by 1.03%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.62

News Sentiment

MiNK Therapeutics has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for MiNK Therapeutics this week, compared to 2 articles on an average week.

Search Interest

Only 3 people have searched for INKT on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.

MarketBeat Follows

3 people have added MiNK Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, MiNK Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

22.48% of the stock of MiNK Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 2.87% of the stock of MiNK Therapeutics is held by institutions.

INKT Stock Analysis - Frequently Asked Questions

How have INKT shares performed this year?

MiNK Therapeutics' stock was trading at $6.9690 at the beginning of 2025. Since then, INKT stock has increased by 100.9% and is now trading at $14.00.

How were MiNK Therapeutics' earnings last quarter?

MiNK Therapeutics, Inc. (NASDAQ:INKT) posted its earnings results on Thursday, August, 14th. The company reported ($1.06) EPS for the quarter, missing the consensus estimate of ($0.55) by $0.51.
Read the conference call transcript.

When did MiNK Therapeutics' stock split?

MiNK Therapeutics's stock reverse split on Tuesday, January 28th 2025.The 1-10 reverse split was announced on Tuesday, January 21st 2025. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 27th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did MiNK Therapeutics IPO?

MiNK Therapeutics (INKT) raised $43 million in an initial public offering on Friday, October 15th 2021. The company issued 3,333,334 shares at $12.00-$14.00 per share.

How do I buy shares of MiNK Therapeutics?

Shares of INKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of MiNK Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that MiNK Therapeutics investors own include Agenus (AGEN), HubSpot (HUBS), Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA) and Bank of America (BAC).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 10/10/2025
• Next Earnings (Estimated): 11/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:INKT
• CIK: 1840229
• Web: www.minktherapeutics.com
• Phone: 212-994-8250
• Fax: N/A
• Employees: 30
• Year Founded: 2017

Price Target and Rating

• Average Price Target for MiNK Therapeutics: $37.50
• High Price Target: $40.00
• Low Price Target: $35.00
• Potential Upside/Downside: +167.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.88)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$9.51 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -227.24%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.15
• Quick Ratio: 0.15

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($4.94) per share
• Price / Book: -2.83

Miscellaneous

• Outstanding Shares: 4,520,000
• Free Float: 3,506,000
• Market Cap: $63.28 million
• Optionable: No Data
• Beta: 0.33